Breaking News
White House Correspondents' Dinner Shooter's Link to NASA and Other Curiosities
US Military Ends 72-Year Mandatory Flu Shot Policy
3 Million Ounces of Gold and 28 Million Ounces of Silver Taken Out the Back Door
Palantir and the New Order
Top Tech News
Researcher wins 1 bitcoin bounty for 'largest quantum attack' on underlying tech
Interceptor-Drone Arms-Race Emerges
A startup called Inversion has introduced Arc, a space-based vehicle...
Mining companies are using cosmic rays to find critical minerals
They regrew a severed nerve - by shortening a bone.
New Robot Ants Work Like Real Insects To Build And Dismantle On Their Own
Russian scientists 'are developing the world's first drug to delay ageing' months after
Sam Altman's World ID Expands Biometric Identity Checks
China Tests Directed Energy Beam That Recharges Drones Mid-Flight
Jurassic Park might arrive sooner than expected, just with Dinobots.
At $2.1 million, newly approved Novartis gene therapy will be world's most expensive drug
Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an inherited neuromuscular disease that causes progressive loss of muscle function. The most severe form of SMA causes infants to die or rely on permanent breathing support by the age of 2. The disease is caused by a defect in a gene that makes SMN, a protein necessary for the survival of motor neurons. Zolgensma uses a re-engineered virus to deliver a functional copy of the defective gene so that SMN protein can be produced.
Novartis is pricing Zolgensma at $2.125 million, or an annualized cost of $425,000 per year for five years, the company said.
Launching Zolgensma will be a big test for Novartis and CEO Vas Narasimhan, now two years on the job. Shareholders expect the gene therapy to deliver blockbuster sales to justify the $8.7 billion that Novartis spent to acquire it last year.